GBA1 and Parkinson disease: Western blotting revealed a significant reduction in glucosylceramidase protein levels in all Gaucher disease, Parkinson’s disease with GBA mutation, E326K/E326K and non-manifesting carrier cell lines (Fig. 1A and B).